C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 14/605 (2006.01) A61K 38/16 (2006.01) A61K 38/22 (2006.01) A61K 47/48 (2006.01) A61P 3/10 (2006.01) C07K 14/575 (2006.01) C07K 16/26 (2006.01) C07K 17/02 (2006.01) C07K 17/08 (2006.01) C12N 15/16 (2006.01) C12P 21/02 (2006.01) C07K 14/72 (2006.01)
Patent
CA 2607566
This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These GLP-1 modified peptides function in vivo as agonists of the GLP-1 receptor. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, for example, type 2 diabetics.
Peptides modifiés offrant des sites de dérivatisation appropriés qui améliorent leurs propriétés pharmacocinétiques. Ces peptides GLP-1 modifiés sont des agonistes in vivo vis-à-vis du récepteur de GLP-1. Ils offrent une solution thérapeutique pour les patients à sécrétion d'insuline endogène diminuée, par exemple dans le diabète de type 2.
Clairmont Kevin
Lumb Kevin
Whelan James
Bayer Healthcare Llc
Bayer Pharmaceuticals Corporation
Borden Ladner Gervais Llp
LandOfFree
Glucagon-like peptide 1 (glp-1) receptor agonists and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Glucagon-like peptide 1 (glp-1) receptor agonists and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glucagon-like peptide 1 (glp-1) receptor agonists and their... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1700045